Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02465957
Recruitment Status : Active, not recruiting
First Posted : June 9, 2015
Last Update Posted : August 14, 2020
Information provided by (Responsible Party):
ImmunityBio, Inc.

Brief Summary:
Phase II study to determine the effects of aNK infusions in combination with ALT-803 in patients with stage III (IIIB) or stage (IV) merkel cell carcinoma (MCC).

Condition or disease Intervention/treatment Phase
Stage IIIB Merkel Cell Carcinoma Stage IV Merkel Cell Carcinoma Biological: aNK (NK-92) Phase 2

Detailed Description:

This is a multi-center, non-randomized, open-label, phase 2 trial to determine the effects of aNK in combination with ALT-803 in patients with stage III (IIIB) or stage IV MCC. The study will use an adaptive Simon optimal two-stage design, which detects efficacy signals, allows for early assessment, and avoids enrolling larger numbers of patients in case of inefficacy.

In the original protocol, an initial cohort of up to 12 patients with stage III (IIIB) or stage IV MCC were to be enrolled and treated with aNK monotherapy (first stage). If the treatment in the first stage improved the 4-month progression free survival (PFS) rate from 4% to 20% (e.g. at least 1 patient out of 12 patients has PFS ≥ 16 weeks [4 months]), then the study would proceed to the second stage, in which 12 more patients were planned to be enrolled and treated. As of July 2016, the trial has met the required efficacy signal defined for the first stage and will continue to enroll a planned total of 24 patients who will receive the combination of aNK and ALT-803. Any patients who are already receiving aNK cells as monotherapy will receive aNK cells in combination with ALT-803 in subsequent cycles.

aNK will be given via IV infusion at a dose of 2 x 10^9 cells/m^2 on two consecutive days (= 1 cycle) every 2 weeks. In addition, ALT-803 will be administered SC at 10 μg/kg on the first day of every aNK infusion (before the aNK infusion) every 2 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Study of aNK (Activated NK-92 Natural Killer Cells) Infusions in Combination With ALT-803 (IL-15) in Patients With Stage III (IIIB) or Stage IV Merkel Cell Carcinoma (MCC)
Study Start Date : August 2015
Actual Primary Completion Date : May 2018
Estimated Study Completion Date : December 31, 2020

Arm Intervention/treatment
Experimental: aNK (NK-92)
aNK (activated NK-92, formerly Neukoplast)
Biological: aNK (NK-92)
A natural killer cell line recovered from a patient with large granular lymphoma
Other Name: NK-92, Neukoplast

Primary Outcome Measures :
  1. Progression Free Survival [ Time Frame: 4 months ]
    Determine the effect of aNK infusions in combination with ALT-803 on the 4-month (~16 weeks) progression-free survival (PFS) rate in patients with stage III (IIIB) or stage IV MCC based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

Secondary Outcome Measures :
  1. Overall Response Rate [ Time Frame: 16 weeks ]
    Determine the overall response rate, as assessed by RECIST at week 16

  2. Time to disease progression [ Time Frame: 4 months ]
    Time to disease progression

  3. Overall survival [ Time Frame: 4 months ]
    Overall survival

  4. Safety and tolerability of aNK in combination with ALT-803 [ Time Frame: 4 months ]
    Assess the safety and tolerability of aNK in combination with ALT-803

  5. Quality of life assessment [ Time Frame: 4 months ]
    Quality of life assessment (FACT-G)

Other Outcome Measures:
  1. Exploratory Genomic, Transcriptomic, and Proteomic Analysis [ Time Frame: 5 years ]
    To determine the genomic, transcriptomic, and proteomic profile of subjects' tumors to identify gene mutations, gene amplifications, RNA-expression levels, and protein-expression levels. Correlations between genomic, transcriptomic, and proteomic profiles and efficacy outcomes will be assessed.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female patients 18 years of age or older.
  2. Patients must have histologically confirmed MCC that is Stage III (IIIB) or Stage IV, as defined by the 2010 AJCC staging criteria for MCC. MCC of unknown primary is allowed.
  3. Prior systemic cytotoxic chemotherapies and/or novel immunotherapy treatments for MCC are allowed. A wash-out period of 2 weeks prior to aNK treatment will be required.
  4. ECOG performance status of 0-2.
  5. Voluntary written informed consent must be given before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care.
  6. Mandatory diagnostic biopsy and whole blood sample are required. The tumor biopsy tissue will be analyzed for the presence of immune cells and will also undergo genomic, transcriptomic, and proteomic profiling.

Exclusion Criteria:

  1. Major surgery within 30 days before study entry.
  2. Any of the following clinical laboratory values at the time of enrollment:

    1. Absolute neutrophil count (ANC) < 1,000 cells/mm^3.
    2. Platelets < 50,000 x 10^9/L.
  3. Liver function abnormalities as indicated by ongoing hepatic enzyme elevation (e.g. AST, ALT, GGT) > 2 x the ULN. Elevation related to direct tumor infiltration is allowed.
  4. Renal insufficiency as indicated by a creatinine level > 2 x the ULN.
  5. Myocardial infarction within 6 months prior to enrollment or New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled arrhythmias, or electrocardiographic evidence of acute ischemia or significant conduction system abnormalities in the opinion of the Investigator. Prior to study entry any known abnormality on an electrocardiogram (ECG) must be determined and documented by the Investigator to be not clinically significant to the patient participation in this study.
  6. Any condition, including laboratory abnormalities, that in the opinion of the Investigator places the patient at unacceptable risk if he/she were to participate in the study. This includes, but is not limited to, serious medical conditions or psychiatric illness likely to interfere with participation in this clinical study.
  7. Female patients who are pregnant or breastfeeding. Female patients of childbearing potential must have a negative pregnancy test and agree to use adequate contraception for the duration of the trial.
  8. Patients with other malignancies or brain metastasis are not eligible; however, given the frequent coexistence of MCC with other malignancies, the following exceptions are allowed:

    1. Patients who have been continuously disease-free for any solid tumor malignancy >3 years prior to the time of enrollment.
    2. Patients with basal cell carcinoma or squamous cell carcinoma.
    3. Patients with prior history of in situ cancer (e.g., breast, melanoma, squamous cells carcinoma of the skin, cervical).
    4. Patients with prior history of prostate cancer that is not under active systemic treatment (except hormonal therapy), but with undetectable PSA (<0.2 ng/mL).
    5. Patients with chronic non-T-cell-based lymphocytic leukemia are eligible if they have isolated lymphocytosis (Rai stage O) on the condition that they do not require systemic treatment for their disease ["B" symptoms, Richter's transformation, lymphocyte doubling time (<6 months) and they do not have lymphadenopathy of hepatosplenomegaly].
    6. Patients with non-T-cell-based lymphoma of any type or hairy cell leukemia are eligible on the condition that they do not receive active systemic treatment for their hematologic disease and are in complete remission as evidenced by PET/CT scans and bone marrow biopsies for at least 3 months.
  9. Patients on immunosuppressants, systemic corticosteroids, or any other investigational product.
  10. Patients unwilling to consent to analysis of their tumor tissue.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02465957

Layout table for location information
United States, Illinois
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, United States, 60611
United States, Pennsylvania
UPMC Cancer Center
Pittsburgh, Pennsylvania, United States, 15232
United States, Washington
Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109
Sponsors and Collaborators
ImmunityBio, Inc.
Layout table for additonal information
Responsible Party: ImmunityBio, Inc. Identifier: NCT02465957    
Other Study ID Numbers: QUILT-3.009
MCC-001 ( Other Identifier: NantKwest, Inc. )
First Posted: June 9, 2015    Key Record Dates
Last Update Posted: August 14, 2020
Last Verified: August 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ImmunityBio, Inc.:
Merkel Cell Carcinoma
Natural Killer Cell
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Merkel Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Polyomavirus Infections
DNA Virus Infections
Virus Diseases
Tumor Virus Infections
Carcinoma, Neuroendocrine
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue